Summit Therapeutics - SMMT Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SMMT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View SMMT analyst ratings or view top-rated stocks.

Summit Therapeutics' stock was trading at $2.69 at the start of the year. Since then, SMMT stock has decreased by 55.0% and is now trading at $1.21.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our SMMT earnings forecast.

Summit Therapeutics Inc. (NASDAQ:SMMT) issued its quarterly earnings data on Thursday, August, 11th. The company reported ($0.17) earnings per share (EPS) for the quarter. The business had revenue of $3.25 million for the quarter. Summit Therapeutics had a negative trailing twelve-month return on equity of 112.66% and a negative net margin of 879.62%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Summit Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.47%), UBS Group AG (0.06%), Renaissance Technologies LLC (0.05%), Hoylecohen LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ankur Dhingra, David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends.

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SMMT stock can currently be purchased for approximately $1.21.

Summit Therapeutics (NASDAQ:SMMT) has a market capitalization of $118.73 million and generates $22.78 million in revenue each year. The company earns $-88,600,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

The company employs 105 workers across the globe.

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The official website for the company is www.summitplc.com. The company can be reached via phone at 617-514-7149, via email at investors@summitplc.com, or via fax at 44-12-3544-3999.